Highly  ||| S:0 E:7 ||| RB
specific  ||| S:7 E:16 ||| JJ
ubiquitin-competing  ||| S:16 E:36 ||| JJ
molecules  ||| S:36 E:46 ||| NNS
effectively  ||| S:46 E:58 ||| RB
promote  ||| S:58 E:66 ||| VB
frataxin  ||| S:66 E:75 ||| JJ
accumulation  ||| S:75 E:88 ||| NN
and  ||| S:88 E:92 ||| CC
partially  ||| S:92 E:102 ||| RB
rescue  ||| S:102 E:109 ||| VB
the  ||| S:109 E:113 ||| DT
aconitase  ||| S:113 E:123 ||| JJ
defect  ||| S:123 E:130 ||| NN
in  ||| S:130 E:133 ||| IN
Friedreich  ||| S:133 E:144 ||| NNP
ataxia  ||| S:144 E:151 ||| FW
cells  ||| S:151 E:157 ||| FW
Friedreich  ||| S:157 E:168 ||| FW
ataxia  ||| S:168 E:175 ||| FW
is  ||| S:175 E:178 ||| VBZ
an  ||| S:178 E:181 ||| DT
inherited  ||| S:181 E:191 ||| JJ
neurodegenerative  ||| S:191 E:209 ||| JJ
disease  ||| S:209 E:217 ||| NN
that  ||| S:217 E:222 ||| WDT
leads  ||| S:222 E:228 ||| VBZ
to  ||| S:228 E:231 ||| TO
progressive  ||| S:231 E:243 ||| JJ
disability ||| S:243 E:253 ||| NN
.  ||| S:253 E:255 ||| .
There  ||| S:255 E:261 ||| EX
is  ||| S:261 E:264 ||| VBZ
currently  ||| S:264 E:274 ||| RB
no  ||| S:274 E:277 ||| DT
effective  ||| S:277 E:287 ||| JJ
treatment  ||| S:287 E:297 ||| NN
and  ||| S:297 E:301 ||| CC
patients  ||| S:301 E:310 ||| NNS
die  ||| S:310 E:314 ||| VBP
prematurely ||| S:314 E:325 ||| RB
.  ||| S:325 E:327 ||| .
The  ||| S:327 E:331 ||| DT
underlying  ||| S:331 E:342 ||| JJ
genetic  ||| S:342 E:350 ||| JJ
defect  ||| S:350 E:357 ||| NN
leads  ||| S:357 E:363 ||| VBZ
to  ||| S:363 E:366 ||| TO
reduced  ||| S:366 E:374 ||| JJ
expression  ||| S:374 E:385 ||| NN
of  ||| S:385 E:388 ||| IN
the  ||| S:388 E:392 ||| DT
mitochondrial  ||| S:392 E:406 ||| JJ
protein  ||| S:406 E:414 ||| NN
frataxin ||| S:414 E:422 ||| NN
.  ||| S:422 E:424 ||| .
Frataxin  ||| S:424 E:433 ||| FW
insufficiency  ||| S:433 E:447 ||| FW
causes  ||| S:447 E:454 ||| FW
mitochondrial  ||| S:454 E:468 ||| FW
dysfunction  ||| S:468 E:480 ||| FW
and  ||| S:480 E:484 ||| CC
ultimately  ||| S:484 E:495 ||| RB
cell  ||| S:495 E:500 ||| JJ
death ||| S:500 E:505 ||| NN
,  ||| S:505 E:507 ||| ,
particularly  ||| S:507 E:520 ||| RB
in  ||| S:520 E:523 ||| IN
peripheral  ||| S:523 E:534 ||| JJ
sensory  ||| S:534 E:542 ||| JJ
ganglia ||| S:542 E:549 ||| NN
.  ||| S:549 E:551 ||| .
There  ||| S:551 E:557 ||| EX
is  ||| S:557 E:560 ||| VBZ
an  ||| S:560 E:563 ||| DT
inverse  ||| S:563 E:571 ||| JJ
correlation  ||| S:571 E:583 ||| NN
between  ||| S:583 E:591 ||| IN
the  ||| S:591 E:595 ||| DT
amount  ||| S:595 E:602 ||| NN
of  ||| S:602 E:605 ||| IN
residual  ||| S:605 E:614 ||| JJ
frataxin  ||| S:614 E:623 ||| NN
and  ||| S:623 E:627 ||| CC
the  ||| S:627 E:631 ||| DT
severity  ||| S:631 E:640 ||| NN
of  ||| S:640 E:643 ||| IN
disease  ||| S:643 E:651 ||| NN
progression ||| S:651 E:662 ||| NNS
;  ||| S:662 E:664 ||| :
therefore ||| S:664 E:673 ||| RB
,  ||| S:673 E:675 ||| ,
therapeutic  ||| S:675 E:687 ||| JJ
approaches  ||| S:687 E:698 ||| NNS
aiming  ||| S:698 E:705 ||| VBG
at  ||| S:705 E:708 ||| IN
increasing  ||| S:708 E:719 ||| VBG
frataxin  ||| S:719 E:728 ||| JJ
levels  ||| S:728 E:735 ||| NNS
are  ||| S:735 E:739 ||| VBP
expected  ||| S:739 E:748 ||| VBN
to  ||| S:748 E:751 ||| TO
improve  ||| S:751 E:759 ||| VB
patients ||| S:759 E:767 ||| NNS
'  ||| S:767 E:769 ||| POS
conditions ||| S:769 E:779 ||| NNS
.  ||| S:779 E:781 ||| .
We  ||| S:781 E:784 ||| PRP
previously  ||| S:784 E:795 ||| RB
discovered  ||| S:795 E:806 ||| VBN
that  ||| S:806 E:811 ||| IN
a  ||| S:811 E:813 ||| DT
significant  ||| S:813 E:825 ||| JJ
amount  ||| S:825 E:832 ||| NN
of  ||| S:832 E:835 ||| IN
frataxin  ||| S:835 E:844 ||| JJ
precursor  ||| S:844 E:854 ||| NN
is  ||| S:854 E:857 ||| VBZ
degraded  ||| S:857 E:866 ||| VBN
by  ||| S:866 E:869 ||| IN
the  ||| S:869 E:873 ||| DT
ubiquitin ||| S:873 E:882 ||| JJ
/ ||| S:882 E:883 ||| CD
proteasome  ||| S:883 E:894 ||| JJ
system  ||| S:894 E:901 ||| NN
before  ||| S:901 E:908 ||| IN
its  ||| S:908 E:912 ||| PRP$
functional  ||| S:912 E:923 ||| JJ
mitochondrial  ||| S:923 E:937 ||| JJ
maturation ||| S:937 E:947 ||| NN
.  ||| S:947 E:949 ||| .
We  ||| S:949 E:952 ||| PRP
also  ||| S:952 E:957 ||| RB
provided  ||| S:957 E:966 ||| VBN
evidence  ||| S:966 E:975 ||| NN
for  ||| S:975 E:979 ||| IN
the  ||| S:979 E:983 ||| DT
therapeutic  ||| S:983 E:995 ||| JJ
potential  ||| S:995 E:1005 ||| NN
of  ||| S:1005 E:1008 ||| IN
small  ||| S:1008 E:1014 ||| JJ
molecules  ||| S:1014 E:1024 ||| NNS
that  ||| S:1024 E:1029 ||| IN
increase  ||| S:1029 E:1038 ||| NN
frataxin  ||| S:1038 E:1047 ||| NN
levels  ||| S:1047 E:1054 ||| NNS
by  ||| S:1054 E:1057 ||| IN
docking  ||| S:1057 E:1065 ||| NN
on  ||| S:1065 E:1068 ||| IN
the  ||| S:1068 E:1072 ||| DT
frataxin  ||| S:1072 E:1081 ||| JJ
ubiquitination  ||| S:1081 E:1096 ||| JJ
site ||| S:1096 E:1100 ||| NN
,  ||| S:1100 E:1102 ||| ,
thus  ||| S:1102 E:1107 ||| RB
preventing  ||| S:1107 E:1118 ||| VBG
frataxin  ||| S:1118 E:1127 ||| JJ
ubiquitination  ||| S:1127 E:1142 ||| NN
and  ||| S:1142 E:1146 ||| CC
degradation ||| S:1146 E:1157 ||| NN
.  ||| S:1157 E:1159 ||| .
We  ||| S:1159 E:1162 ||| PRP
called  ||| S:1162 E:1169 ||| VBD
these  ||| S:1169 E:1175 ||| DT
compounds  ||| S:1175 E:1185 ||| JJ
ubiquitin-competing  ||| S:1185 E:1205 ||| JJ
molecules  ||| S:1205 E:1215 ||| NNS
( ||| S:1215 E:1216 ||| -LRB-
UCM ||| S:1216 E:1219 ||| NNP
) ||| S:1219 E:1220 ||| -RRB-
.  ||| S:1220 E:1222 ||| .
By  ||| S:1222 E:1225 ||| IN
extending  ||| S:1225 E:1235 ||| VBG
our  ||| S:1235 E:1239 ||| PRP$
search  ||| S:1239 E:1246 ||| NN
for  ||| S:1246 E:1250 ||| IN
effective  ||| S:1250 E:1260 ||| JJ
UCM ||| S:1260 E:1263 ||| NNP
,  ||| S:1263 E:1265 ||| ,
we  ||| S:1265 E:1268 ||| PRP
identified  ||| S:1268 E:1279 ||| VBD
a  ||| S:1279 E:1281 ||| DT
set  ||| S:1281 E:1285 ||| NN
of  ||| S:1285 E:1288 ||| IN
new  ||| S:1288 E:1292 ||| JJ
and  ||| S:1292 E:1296 ||| CC
more  ||| S:1296 E:1301 ||| RBR
potent  ||| S:1301 E:1308 ||| JJ
compounds  ||| S:1308 E:1318 ||| NN
that  ||| S:1318 E:1323 ||| IN
more  ||| S:1323 E:1328 ||| RBR
efficiently  ||| S:1328 E:1340 ||| RB
promote  ||| S:1340 E:1348 ||| VB
frataxin  ||| S:1348 E:1357 ||| JJ
accumulation ||| S:1357 E:1369 ||| NN
.  ||| S:1369 E:1371 ||| .
Here  ||| S:1371 E:1376 ||| RB
we  ||| S:1376 E:1379 ||| PRP
show  ||| S:1379 E:1384 ||| VBP
that  ||| S:1384 E:1389 ||| IN
these  ||| S:1389 E:1395 ||| DT
compounds  ||| S:1395 E:1405 ||| NN
directly  ||| S:1405 E:1414 ||| RB
interact  ||| S:1414 E:1423 ||| VBN
with  ||| S:1423 E:1428 ||| IN
frataxin  ||| S:1428 E:1437 ||| NN
and  ||| S:1437 E:1441 ||| CC
prevent  ||| S:1441 E:1449 ||| VB
its  ||| S:1449 E:1453 ||| PRP$
ubiquitination ||| S:1453 E:1467 ||| NN
.  ||| S:1467 E:1469 ||| .
Interestingly ||| S:1469 E:1482 ||| RB
,  ||| S:1482 E:1484 ||| ,
these  ||| S:1484 E:1490 ||| DT
UCM  ||| S:1490 E:1494 ||| NNP
are  ||| S:1494 E:1498 ||| VBP
not  ||| S:1498 E:1502 ||| RB
effective  ||| S:1502 E:1512 ||| JJ
on  ||| S:1512 E:1515 ||| IN
the  ||| S:1515 E:1519 ||| DT
ubiquitin-resistant  ||| S:1519 E:1539 ||| JJ
frataxin  ||| S:1539 E:1548 ||| JJ
mutant ||| S:1548 E:1554 ||| NN
,  ||| S:1554 E:1556 ||| ,
indicating  ||| S:1556 E:1567 ||| VBG
their  ||| S:1567 E:1573 ||| PRP$
specific  ||| S:1573 E:1582 ||| JJ
action  ||| S:1582 E:1589 ||| NN
on  ||| S:1589 E:1592 ||| IN
preventing  ||| S:1592 E:1603 ||| VBG
frataxin  ||| S:1603 E:1612 ||| JJ
ubiquitination ||| S:1612 E:1626 ||| NN
.  ||| S:1626 E:1628 ||| .
Most  ||| S:1628 E:1633 ||| RBS
importantly ||| S:1633 E:1644 ||| RB
,  ||| S:1644 E:1646 ||| ,
these  ||| S:1646 E:1652 ||| DT
compounds  ||| S:1652 E:1662 ||| NNS
are  ||| S:1662 E:1666 ||| VBP
able  ||| S:1666 E:1671 ||| JJ
to  ||| S:1671 E:1674 ||| TO
promote  ||| S:1674 E:1682 ||| VB
frataxin  ||| S:1682 E:1691 ||| JJ
accumulation  ||| S:1691 E:1704 ||| NN
and  ||| S:1704 E:1708 ||| CC
aconitase  ||| S:1708 E:1718 ||| JJ
rescue  ||| S:1718 E:1725 ||| NN
in  ||| S:1725 E:1728 ||| IN
cells  ||| S:1728 E:1734 ||| NNS
derived  ||| S:1734 E:1742 ||| VBN
from  ||| S:1742 E:1747 ||| IN
patients ||| S:1747 E:1755 ||| NNS
,  ||| S:1755 E:1757 ||| ,
strongly  ||| S:1757 E:1766 ||| RB
supporting  ||| S:1766 E:1777 ||| VBG
their  ||| S:1777 E:1783 ||| PRP$
therapeutic  ||| S:1783 E:1795 ||| JJ
potential ||| S:1795 E:1804 ||| NN
.  ||| S:1804 E:1806 ||| .
